Clinical trial
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients…
NCT00461851 · Yale University, Other · Completed
Key facts
| NCT number | NCT00461851 |
|---|---|
| Title | Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma |
| Official title | A Phase II, Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma |
| Lead sponsor | Yale University, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Carboplatin, Sorafenib |
| Enrollment | 17 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Apr 18, 2007 |
| Last update posted | Dec 14, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: